Tissue Recovery

onlinelibrary.wiley.com

A Pilot trial evaluating meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia

1. Daniel Lukaczer1,*,
2. Gary Darland2,
3. Matthew Tripp3,
4. De Ann Liska4,
5. Robert H. Lerman1,
6. Barbara Schiltz1,
7. Jeffrey S. Bland5

Article first published online: 31 OCT 2005
DOI: 10.1002/ptr.1709
Copyright © 2005 John Wiley & Sons, Ltd.
Issue

Author Information

1. Clinical Research at the Functional Medicine Research Center, Gig Harbor, WA, a division of Metagenics, Inc.
2. Applied Science for Research and Development at Metagenics, Gig Harbor, WA
3. Research and Development at Metagenics, Gig Harbor, WA
4. Research Information Services at Metagenics, Gig Harbor, WA
5. Metagenics, Gig Harbor, WA

Email: Daniel Lukaczer (DanLukaczer@metagenics.com)
*Correspondence: Daniel Lukaczer, Functional Medicine Research Center, 9770 44th Ave. NW, Suite 102, Gig Harbor, WA 98332, USA.

Abstract

The aim of this open-label, 8-week observational trial was to investigate the efficacy of Meta050 (a proprietary, standardized combination of reduced iso-alpha-acids from hops, rosemary extract and oleanolic acid) on pain in patients with rheumatic disease. Osteoarthritis, rheumatoid arthritis and fibromyalgia patients were given 440 mg Meta050 three times a day for 4 weeks, which was changed to 880 mg twice a day for the subsequent 4 weeks in the majority of patients. Pain and condition-specific symptoms were assessed using a standard visual analog scale (VAS), an abridged arthritis impact measurement scale (AIMS2) and the fibromyalgia impact questionnaire. Fifty-four subjects with rheumatic disease completed the trial. Following treatment, a statistically significant decrease in pain of 50% and 40% was observed in arthritis subjects using the VAS (p < 0.0001; Wilcoxon-ranked sums) and AIMS2 (p < 0.0001), respectively. Fibromyalgia subject scores did not significantly improve. A decreasing trend of C-reactive protein, a marker for inflammation, was also observed in those subjects who presented with elevated C-reactive

 

 

 

 

The information on this website is provided for informational purposes only and is not intended as a substitute for the advice provided by your physician or other healthcare professional. The information and products on this website are not intended to diagnose, treat, cure or prevent any disease.